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license (http://creativebiomarker studies. We investigated the effects of up to four freeze-thaw cycles on single molecule
array immunoassays of serum neurofilament light chain and plasma total tau, amyloid b 1–40
(Aß40), and Ab 1–42 (Ab42).
Methods: Individuals who had peripheral venepuncture during investigation of suspected neurode-
generative disease were recruited. After standardized preprocessing, 200 mL of plasma and serum
aliquots were stored at280Cwithin 60 minutes. Aliquots underwent one to four freeze-thaw cycles.
Results: Therewas no significant difference across four freeze-thaw cycles for serum neurofilament light
chain (n5 12), plasma total tau (n5 11), or plasma Ab42 (n5 12). For plasmaAb40 (n5 14), therewere
significant median reductions by ratios of .96 and .92 at the third and fourth cycles, respectively.
Discussion: Up to four freeze-thaw cycles do not influence single molecule array blood biomarkers
of neurofilament light chain, total tau, or Ab42, with at most minor reductions in Ab40.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Freeze-thaw; Blood; Biomarker; Simoa1. Introduction
Preanalytical factors may be an important source of vari-
ation among studies investigating putative blood-based bio-
markers of Alzheimer’s disease, in which replication across
studies has posed a significant challenge. Guidelines for
standardizing these preanalytic variables have stated that it
is desirable to minimize the number of freeze-thaw cycles
to which samples are exposed [1]. The evidence for this
comes predominantly from studies showing that more than
three freeze-thaw cycles reduce plasma amyloid b 1–40
and 1–42 (Ab40 and Ab42) concentrations by as much asdeclared that no conflict of interest exists.
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commons.org/licenses/by-nc-nd/4.0/).20% [2] and also reduce cerebrospinal fluid (CSF) Ab42 con-
centration [3] as quantified on immunoassay platforms.
There is some conflicting evidence on the stability in CSF
of total tau, which in one report remained stable over up to
six freeze-thaw cycles [3], but in another study, both CSF to-
tal tau and phospho-tau-181 concentrations as measured by
enzyme-linked immunosorbent assay reduced over three
freeze-thaw cycles [4]. Conversely, CSF neurofilament light
chain (NFL) remains stable over up to four freeze-thaw cy-
cles [5]. However, there has been no systematic examination
of the stability of these biomarkers in blood. More recently,
the Single molecule array (Simoa) HD-1 analyzer, a highly
sensitive digital immunoassay platform, has been developed,
which is capable of measuring these and other biomarkers
with sensitivity in the femtomolar range [6]. In this study,
we examined the effects of up to four freeze-thaw cycles
on serum NFL and plasma total tau, Ab40, and Ab42.imer’s Association. This is an open access article under the CC BY-NC-ND
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2.1. Participants
Werecruited individuals seen at the specialist cognitive disor-
ders clinics at the National Hospital for Neurology and Neuro-
surgery, who were having diagnostic lumbar puncture with
paired venous blood testing for investigation of a suspected
neurodegenerative condition. At the time of clinical sampling,
all individuals donated an additional blood sample for research,
andbasic demographic datawere recorded.All participants gave
written informed consent, or for thosewhowere deemed lacking
in capacity to do so by the assessing clinician, proxy consentwas
obtained from a consultee. The study was conducted in accor-
dance with local clinical research regulations and was approved
by the local ethics committee (reference: 12/0344).2.2. Sample handling
The plasma was collected in 8-mL ethylenediaminetetra-
acetic acid tubes and serum in 6.5-mL serum separator tube
gel separator tubes by peripheral venepuncture with a tourni-
quet, using either a 21G or 23G butterfly needle and BD
Vacutainer collecting system. Participants were not in-
structed to fast, but all blood samples for each participant
were taken between 9AMand 1 PMon a single venepuncture.
Plasma and serumwere centrifuged at 1800! g for 5minutes
at room temperature. Plasmawas centrifuged within a median
of 20 minutes after sampling, whereas serum was allowed to
clot for a median of 15 minutes before centrifugation. The su-
pernatant was pipetted into 200-mL aliquots into identical
polypropylene tubes, for freezingat280C,within 60minutes
of sampling, in keeping with current guidelines [1].2.3. Freeze-thaw cycles
Each additional freeze-thaw cycle after the first consisted
of 1 hour of direct thaw to room temperature, followed by
1 hour of direct replacement into 280 C. After the final
thaw, samples were transferred to 1.5-mL polypropylene
centrifuge tubes and centrifuged as per the kit-manufacturer’s
recommendation at 13,000! g for 10minutes, and the super-
natant of each samplewas pipetted onto the plate for analysis.
For each biomarker, all aliquots from the same participant
were assayed using the same batch of reagents in the same run.2.4. Blood fraction choice
To examine the effects of freeze-thaw cycle number, we
chose to measure NFL in serum as we and others have shown
that NFL may be measured reliably in serum to show differ-
ences between disease groups among neurodegenerative dis-
eases [7,8] and that there is a linear relationship between
plasma and serum NFL within individuals, with serum
returning higher values when paired samples are analyzed
on the same run (Supplementary Fig. S1A). Similarly, we
chose to measure total tau, Ab40, and Ab42 in plasma as itreturns higher values than serum for these biomarkers
(Supplementary Fig. S1B–D).
2.5. Analysis
Commercially available Simoa total tau, NFL, Ab40, and
Ab42 kits (Quanterix) were used according to the manufac-
turer’s instructions. The principles of these assays are
similar; a detailed account of the basis of Simoa technology
has been provided by Wilson and colleagues [6].
All measurements were conducted on the same automated
HD-1 analyzer (Quanterix). For serum NFL, plasma Ab40,
and plasma Ab42, all samples were assayed in duplicate.
For plasma tau, all samples were assayed in triplicate because
of kit availability. The mean of the replicates for each sample
was calculated and represented graphically. Results were
included in the analysis if the coefficient of variation across
replicates was ,15%. The number of individuals included
was therefore as follows: serum NFL, 12; plasma total tau,
11; plasma Ab40, 14; and plasma Ab42, 12.
2.6. Statistics
A Friedman analysis of variance (ANOVA) test (nonpara-
metric repeated measures) was used to assess differences
within individuals across four freeze-thaw cycles (SPSS Sta-
tistics, version 24). Where statistically significant differ-
ences were found at the P 5 .05 level, the median ratio of
the concentration at a specific freeze-thaw cycle to the con-
centration at the first cyclewas calculated across individuals.3. Results
Fig. 1 shows the measured concentration of each analyte
against the number of freeze-thaw cycles.
The Friedman ANOVA test showed a two-tailed signifi-
cance of ..05 for a change in the means for serum NFL,
plasma total tau, and plasma Ab42 over four cycles.
For plasma Ab40, the median concentration ratio between
the third and first cycles was .96 (interquartile range, .92–
.99; Friedman ANOVA P5 .015). The median concentration
ratio between the fourth and first cycles was .92 (interquar-
tile range, .90–.96; Friedman ANOVA P 5 .001), and this
survived the exclusion of the one clear outlier individual.4. Discussion
Weshow that for up to four freeze-thawcycles, each consist-
ing of at least 1 hour of thawing to room temperature, in aliquot
volumes of 200mL, there is no consistent trend for change in the
concentrations of serumNFL, plasma total tau, or plasmaAb42
as measured using the Simoa digital immunoassay platform.
We found some evidence for a small reduction in plasma
Ab40 after the third and further after the fourth cycle. This latter
finding is in keeping with the experience of Lachno and col-
leagues, who used a Luminex bead-based immunoassay plat-
form and a 1-hour thaw per cycle to demonstrate a reduction
Serum NFL Plasma total tau






1 2 3 4
pg/ml







1 2 3 4
pg/ml







1 2 3 4
pg/ml






1 2 3 4
pg/ml
Number of freeze-thaw cycles
A B
C D
Fig. 1. Concentration of the biomarker versus number of freeze-thaw cycles for (A) serum NFL, n5 12; (B) plasma total tau, n5 11; (C) plasma Ab40, n5 14;
and (D) Plasma Ab42, n 5 12. Each colored line represents an individual. Abbreviations: Ab, amyloid b; NFL, neurofilament light chain.
A. Keshavan et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 448-451450in plasmaAb 1–40 from the fourth cycle in five individuals [2].
Here,we show, in a larger sample size, a statistically significant,
albeit very small, reduction by amedian ratio of 0.96 at the third
cycle and 0.92 at the fourth cycle relative to the first. The latter
reduction survived removal of an outlier individual for whom
there was a ratio of 0.38 between the concentrations at fourth
and first cycles but no obvious technical difference identified
in sample treatment. It is not clear whether the results from
this outlier were in any way related to the freeze-thaw effect,
but in keeping with the group results, we suggest that samples
in which plasma Ab40 is to be measured should be restricted
to a maximum of two freeze-thaw cycles.
The conditions chosen in this study are consistent with
the aliquot volumes and treatment recommended by current
consensus guidelines [1] and mimic the likely conditions in
large-cohort studies on blood-based biomarkers of neurode-
generative disease, in which minimizing sample volumes is
desirable and cross-validation between laboratories will beessential. The ability to subaliquot samples will allow for
sharing of samples across centers while reducing concerns
about the effects of small numbers of short-duration
freeze-thaw cycles on measured analyte concentrations.
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1. Systematic review: The authors reviewed the litera-
ture using PubMed. There are several publications
on preanalytical factors including the effects of
freeze-thaw cycles on core cerebrospinal fluid
(CSF), biomarkers of Alzheimer’s disease (AD), and
CSF neurofilament light chain (NFL), but there has
been no systematic examination of the effects of
multiple freeze-thaw cycles of these biomarkers in
blood despite the existence of a growing literature on
the use of these blood biomarkers of AD in large
cohorts.
2. Interpretation: This work demonstrates that up to
four freeze-thaw cycles on aliquot volumes of
200 mL do not affect measured concentrations of
serumNFL or plasma total tau and Ab42. Beyond two
freeze-thaw cycles, plasma Ab40 may drop signifi-
cantly in a few samples.
3. Future directions: Sample sharing across research
centers may be facilitated by the ability to freeze
and thaw small aliquots up to the limits described
in this article.References
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